Introduction {#s1}
============

Valproic acid (VPA) is one of the most frequently prescribed antiepileptic drugs ([@CIT0034]) and is also increasingly used for other indications, such as bipolar psychiatric disorder ([@CIT0007]), schizophrenia, borderline personality disorder ([@CIT0023]), and migraine prophylaxis ([@CIT0035]). Antiepileptic therapy often takes years and may even last the entire lifetime of a patient. This highlights the importance of drug safety throughout the course of therapy. It is well known that one side effect of VPA that negatively influences its appeal is a considerable increase in body weight ([@CIT0006]). Weight gain induced by VPA seems to be associated with many metabolic and endocrine disturbances, the most frequent of which are hyperinsulinemia and insulin resistance and hyperleptinemia and leptin (LEP) resistance, which are associated with long-term vascular complications, such as hypertension and atherosclerosis ([@CIT0046]; [@CIT0005]). Therefore, weight gain is the most common reason for patients to discontinue VPA treatment. Several clinical studies have indicated that the frequency and extent of weight gain induced by VPA are highly variable ([@CIT0047]). [@CIT0018] reported a significant weight gain (≥5kg) in 43.6% of women and 23.5% of men on VPA therapy. And [@CIT0047] suggested that an increase of 2kg of body weight after 1 month of treatment should imply considerations to change antiepileptic drug therapy. However, the mechanism through which VPA may induce weight gain is still unknown.

Currently, research studying the effect of VPA on weight gain has focused on various hypotheses, such as dysregulation of the hypothalamic system ([@CIT0030]), hyperleptinaemia, and LEP resistance ([@CIT0022]; [@CIT0024]; [@CIT0047]; [@CIT0027]), but there is no single mechanism that can explain VPA-induced weight gain. Interestingly, some patients taking VPA do not gain weight, and the concordance of weight gain was found in monozygotic twins exposed to VPA ([@CIT0029]), suggesting that genetic variation may play an important role in VPA-related weight gain. Over the past decade, research identifying genes associated with antipsychotic drug-induced weight gain focused on factors that influence the molecular pathways involved in energy homeostasis (e.g., insulin receptor signaling pathway, lipid metabolism), appetite stimulation and satiety inhibition ([@CIT0015]; [@CIT0028]). Neuropeptide Y (*NPY*; [@CIT0013]), melanocortin4 receptor (*MC4R*; [@CIT0013]), *LEP*, leptin receptor (*LEPR*; [@CIT0008]), brain-derived neurotrophic factor (*BDNF*; [@CIT0036]), and serotonergic 2C-receptor (*HTR* ~*2C*~; [@CIT0026]) have been extensively studied.

It has been reported that VPA-treated epileptic patients who gained weight developed an increased appetite and thirst and quenched their thirst with calorie-rich beverages ([@CIT0005]). The genetic variations in the appetite stimulation and energy homeostasis genes are important candidates for exploring the genetic factors involved in VPA-induced weight gain. Previous studies demonstrated that patients treated with VPA who develop obesity have been found to have higher levels of serum insulin and LEP compared with those who do not gain weight ([@CIT0045]). Recently, [@CIT0003] reported that VPA is a novel activator of adenosine monophosphate-activated protein kinase (AMPK), a key regulator of cellular metabolism, using primary mouse and human hepatocytes. Genetic variants in the dopamine 2 receptor gene (*DRD2*) and ankyrin repeat and kinase domain containing 1 gene (*ANKK1*) influence the functioning of the dopamine-mediated reward circuitry in the brain and the risks of overeating and obesity ([@CIT0010]), and it has been demonstrated that VPA can potentiate *DRD2* activity ([@CIT0031]). Previous literature also reported that VPA can increase *NPY*, *BDNF,* and methylenetetrahydrofolate reductase (*MTHFR*) gene expression ([@CIT0041]; [@CIT0019]; [@CIT0001]), which are related to appetite stimulation and energy homeostasis ([@CIT0028]). Thus, multiple genes are probably involved in VPA-induced weight gain; however, there is a paucity of pharmacogenetic research on VPA-induced weight gain ([@CIT0011]). Therefore, a comprehensive analysis of genetic polymorphisms that may relate to VPA-induced weight gain is necessary.

Aside from genetic factors, the relationship between VPA concentration and VPA-induced weight gain has been being disputed ([@CIT0025]; [@CIT0044]; [@CIT0009]; [@CIT0037]; [@CIT0016]), so it is necessary to clarify the relationship between steady state plasma concentrations (Css) of VPA and weight change with a large patient group.

Based on these observations, in the present study we carried out a multi-gene analysis to investigate the role of genetic variants in VPA-induced weight gain in epilepsy patients and attempted to analyze the association of VPA concentration with VPA-induced weight gain.

Methods {#s2}
=======

Study Population {#s3}
----------------

A total of 212 epilepsy patients who received VPA (200--1250mg/day) were enrolled at the Department of Neurology at the First Afﬁliated Hospital of Sun Yat-sen University. All patients had been diagnosed with epilepsy, and had normal liver and kidney functions based on results from electroencephalograms and biochemical laboratory tests. The exclusion criteria for this study included pregnancy, infancy, severe head injuries, previous medical conditions that required treatment and were not stable (hepatitis C, HIV, thyroid disorder, or diabetes mellitus), substance dependence, clinically-relevant mental retardation, and severe personality disorder. The protocol of this study was approved by the Human Investigation Ethics Committee of the School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China (Clinicaltrials.gov Identiﬁer No. NCT01172626), and written consent was obtained from all patients prior to enrollment. The dosing regimen was maintained stably for at least 1 month to ensure that the blood sampling was performed at the VPA Css. At 1, 3, and 6 months after receiving VPA, venous blood samples (2mL) were collected for analysis immediately before taking morning medications. Height and weight for the determination of body mass index (BMI) were measured on the initiation of VPA treatment and at monthly physician visits, and weight gain was determined by a change in BMI over the treatment period. An increase in weight of ≥7% was defined as significant weight gain. From the 212 patients, 121 patients received VPA monotherapy and 91 patients received a combination therapy of VPA with either lamotrigine (n = 72), carbamazepine (n = 12), or oxcarbazepine (n = 7). These other treatments were included in this study because these drugs are known to have little inﬂuence on weight change ([@CIT0038]).

Genetic Analyses {#s4}
----------------

Previous literature has reported associations of several factors with VPA-induced weight gain ([@CIT0047]). The single nucleotide polymorphisms (SNPs) studied in our research are the following: *NPY*: rs16147 and rs3037354; *MC4R*: rs17782313, rs489693, and rs8087522; *LEP*: rs10954173 and rs3828942; *LEPR*: rs1137101 and rs1327120; *BDNF*: rs6265 and rs1519480; fat mass and obesity associated: rs9939609; *ANKK1*: rs1800497; *DRD2*: rs1079598; α2 catalytic subunit of AMPK (*PRKAA2*): rs10789038; β2 non-catalytic subunit of AMPK (*PRKAB2*): rs3766522; γ3 non-catalytic subunit of AMPK: rs692243; *MTHFR*: rs1801133; and *HTR* ~*2C*~: rs3813929. DNA was obtained from peripheral blood (2mL) and was extracted according to a previously described method ([@CIT0033]). Genotyping of all polymorphisms was carried out with the Sequenom MassArray technology platform (Sequenom). The DNA absorbance ratio (A260/A280) was greater than 1.8 to ensure high quality, and the concentrations were determined by NanoDrop 2000 (Thermo). For data acquisition and analyses, the MassArray Typer 4.0 software was used. Inspection of the clusters was carried out to ensure a clear cluster separation with satisfactory signal-to-noise cutoff. SpectroChip results with less than 99.5% concordance in duplicate checks along with more than a 10% call rate in a blank check or with more than a 25% call rate in the blank control were considered failed and were repeated.

### Quantification of the VPA Plasma Concentration {#s5}

VPA Css were determined by the high-performance liquid chromatography ultraviolet (HPLC-UV) method (Waters 1525-717-2487 HPLC system; [@CIT0012]). The calibration curves ranged from 5.0--200 μg/mL. The accuracy and precision data for the intra- and inter-day plasma samples were \<15% and could be used to accurately determine VPA concentrations in plasma.

Statistical Analysis {#s6}
--------------------

All statistical analyses of the results were performed using SPSS version 21.0. Categorical variables were compared using Pearson χ^2^ test, and continuous variables were analyzed using the independent *t*-test for normally-distributed variables or the Mann--Whitney U-test for the non-normally-distributed variables to compare the means between the two subgroups. The patients included in this study varied in gender, age, and baseline BMI. To avoid these confounding factors, analyses of covariance were used for association tests between genotype and BMI change (from baseline) as the dependent variable, with gender, age, and baseline BMI as the covariates. Bonferroni's corrections were used for multiple comparisons. Haploview 4.2 was used to determine the deviation from the Hardy--Weinberg equilibrium ([@CIT0004]). Statistical signiﬁcance was assumed for *p* values less than 0.05.

Results {#s7}
=======

Clinical Characteristics and Genotype Results {#s8}
---------------------------------------------

The clinical characteristics of the study population (n = 212) are summarized in [Table 1](#T1){ref-type="table"}. The allelic distributions of all of the SNPs detected in this study were consistent with the Hardy--Weinberg equilibrium (*p* \> 0.05), except for *HTR* ~*2C*~ rs 3813929, which is a promoter polymorphism of the X-linked *HTR* ~*2C*~ gene. [Table 2](#T2){ref-type="table"} summarizes all 19 SNP polymorphisms, with the allele frequencies and *p*-values of the allelic association of each polymorphism with the BMI change. Of these, we observed three polymorphisms---*LEPR* rs1137101, *ANKK1* rs1800497, and *PRKAA2* rs10789038---that were associated with a BMI increase within 6 months after initiation of VPA treatment (*p* \< 0.001, *p* = 0.017, and *p* = 0.020, respectively; [Table 3](#T3){ref-type="table"}). After correcting for Bonferroni multiple tests (19 SNPs, *p* ~*corrected*~ = 0.0026), the difference observed in *LEPR* rs1137101 remained significant. For allelic association analyses, all of the allele frequencies were close to the allele frequency data of the reference HapMap population (<http://www.ncbi.nlm.nih.gov/snp/>). Among these alleles, we found that patients who were carriers of the A allele of *LEPR* rs1137101 gained significantly more weight than those with the GG genotype (AA+AG vs GG, *p* \< 0.001). Patients who were carriers of the C allele of *ANKK1* rs1800497 gained significantly more weight than those with the TT genotype (CC+CT vs TT, *p* = 0.0021). Similarly, for *PRKAA2* rs10789038, the G allele carriers had greater changes in BMI than AA genotype carriers (GG+AG vs AA, *p* = 004). The statistical significance under the dominant model of *LEPR* rs1137101 and the recessive model of *ANKK1* rs1800497 were also found after correction for Bonferroni multiple testing (19 SNPs, *p* ~*corrected*~ = 0.0026; [Figure 1](#F1){ref-type="fig"}). Except for these, other alleles were found to have no relationship with BMI change in our study.

###### 

Clinical and Demographic Characteristics of the Samples (n = 212)

  Characteristics                Sample (n = 212)
  ------------------------------ ------------------
  Age (years)                    24.9±10.0
  Gender                         
  Male/female                    126/86
  Baseline weight (kg)           58.13±12.85
  Weight after 6 months (kg)     60.38±13.74
  Baseline BMI (kg/m^2^)         21.42±3.38
  BMI after 6 months (kg/m^2^)   22.17±3.73
  Drug prescribed                
  VPA monotherapy                121
  VPA+LTG                        72
  VPA+CBZ                        12
  VPA+OXC                        7
  Dosage of VPA (mg/day)         200--1250
  VPA Css (μg/mL)                58.4±25.4

CBZ, carbamazepine; Css, steady state plasma concentrations; LTG, lamotrigine; OXC, oxcarbazepine; VPA, valproic acid.

###### 

Genotypes and the Association with BMI Gain for the Total Sample (n = 212)

  ---------------------------------------------------------------------------------------------------------------------------------------------
  Gene     SNP          BMI gain (kg/m^2^) (n)   *p*-value^a^          Gene           SNP          BMI gain (kg/m^2^) (n)   *p*-value^a^
  -------- ------------ ------------------------ --------------------- -------------- ------------ ------------------------ -------------------
  *NPY*    rs16147      AA 0.79±1.21 (29)        0.227                 *BDNF*         rs1519480    CC 0.87±1.3 (19)         0.906

                        AG 0.57±0.89 (92)                                                          CT 0.69±1.22 (94)        

                        GG 0.93±1.43 (91)                                                          TT 0.79±1.18 (99)        

           rs3037354    TG/TG 0.89±1.23 (91)     0.105                 *FTO*          rs9939609    AA 1.2±1.3 (4)           0.780

                        TG/- 0.55±0.91 (99)                                                        AT 0.83±1.17 (40)        

                        -/- 1.05±1.86 (22)                                                         TT 0.72±1.21 (168)       

  *MC4R*   rs17782313   CC 0.41±0.6 (9)          0.429                 *ANKK1*        rs1800497    CC 1.01±1.37 (73)        0.017^b^

                        CT 0.92±1.47 (66)                                                          CT 0.76±1.22 (91)        

                        TT 0.69±1.07 (137)                                                         TT 0.35±0.69 (48)        

           rs489693     AA 0.87±0.81 (9)         0.617                 *DRD2*         rs1079598    CC 0.55±0.83 (42)        0.583

                        AC 0.62±0.99 (78)                                                          CT 0.76±1.27 (113)       

                        CC 0.83±1.34 (125)                                                         TT 0.89±1.29 (57)        

           rs8087522    AA 0.45±0.83 (4)         0.868                 *PRKAA2*       rs10789038   AA 0.69±1.27 (150)       0.020^b^

                        AG 0.74±1.0 (53)                                                           AG 0.87±0.99 (54)        

                        GG 0.76±1.27 (155)                                                         GG 1.23±1.08 (8)         

  *LEP*    rs10954173   AA 0.61±0.91 (12)        0.110                 *PRKAB2*       rs3766522    AA 0.67±0.85 (5)         0.794

                        AG 0.57±1.25 (73)                                                          AT 0.66±0.89 (56)        

                        GG 0.87±1.15 (127)                                                         TT 0.79±1.31 (151)       

           rs3828942    AA 0.8±1.16 (103)        0.562                 *PRAKG3*       rs692243     CC 0.76±1.1 (52)         0.334

                        AG 0.75±1.3 (91)                                                           CG 0.81±1.26 (117)       

                        GG 0.5±0.88 (18)                                                           GG 0.59±1.16 (43)        

  *LEPR*   rs1137101    AA 1.71±1.49 (4)         **\<** 0.001^**c**^   *MTHFR*        rs1801133    CC 0.85±1.33 (119)       0.357

                        AG 1.19±1.18 (46)                                                          CT 0.62±1.04 (76)        

                        GG 0.6±1.17 (162)                                                          TT 0.65±0.9 (17)         

           rs1327120    AA 0.74±1.21 (176)       0.574                 *HTR* ~*2C*~   rs3813929    C/CC 0.74±1.20 (181)     0.508 (Total)

                        AG 0.73±1.13 (32)                                                          CT 0.68±1.04 (12)        

                        GG 1.37±1.69 (4)                                                           T/TT 0.94±1.34 (19)      

  *BDNF*   rs6265       AA 0.78±1.53 (43)        0.850                                rs3813929    CC 0.62±1.01 (72)        0.774 (Female)^d^

                        AG 0.78±1.09 (111)                                                         CT/TT 0.57±0.95 (14)     

                        GG 0.68±1.13 (58)                                             rs3813929    C 0.82±1.32 (109)\       0.204 (Male)^d^
                                                                                                   T 1.07±1.42 (17)         
  ---------------------------------------------------------------------------------------------------------------------------------------------

^a^ Analyses of covariance with gender, age, and baseline BMI (kg/m^2^) as covariates.

^b^ *p* \< 0.05.

^c^ The association of rs1137101 with BMI change remained signiﬁcant after the Bonferroni correction, which was set at *p* \< 0.0026 (0.05/19 SNPs).

^d^ Sex-specific analyses for *HTR* ~*2C*~ rs3813929 (on the X chromosome); *p*-values calculated using Mann--Whitney U.

AMPK, AMP-activated protein kinase; *ANKK1,* ankyrin repeat kinase domain containing 1; *BDNF,* brain-derived neurotrophic factor; *DRD2,* dopamine 2 receptor gene; *FTO,* fat mass and obesity associated; *HTR* ~*2C,*~ serotonergic 2C-receptor; *LEP,* leptin; *LEPR,* leptin receptor; *MC4R,* melanocortin4 receptor; *MTHFR,* methylenetetrahydrofolate reductase; *NPY,* neuropeptide Y; *PRKAA2,* α2 catalytic subunit of AMPK; *PRKAB2,* β2 non-catalytic subunit of AMPK; *PRAKG3,* γ3 non-catalytic subunit of AMPK; *SNP*, single nucleotide polymorphism.

###### 

The Association Between *LEPR* rs1137101, *ANKK1* rs1800497, and *PRKAA2* rs10789038 Genotypes with BMI Gain Within 6 Months After Initiation of VPA Treatment (n = 212)

                        1 month     2 months    3 months    4 months    5 months    6 months
  --------------------- ----------- ----------- ----------- ----------- ----------- -------------
  *LEPR* rs1137101                                                                  
   AA                   0.08±0.09   0.40±0.30   0.89±0.66   1.23±1.01   1.45±1.23   1.71±1.49
   AG                   0.08±0.14   0.28±0.34   0.63±0.64   0.86±0.87   1.05±1.06   1.19±1.18
   GG                   0.05±0.18   0.22±0.42   0.34±0.68   0.45±0.87   0.55±1.06   0.6±1.17
   *p*-value^a^         0.448       0.184       0.004^b^    0.002^c^    0.002^c^    \< 0.001^c^
  *ANKK1* rs1800497                                                                 
   CC                   0.07±0.17   0.28±0.42   0.57±0.78   0.76±1.03   0.90±1.22   1.01±1.37
   CT                   0.07±0.22   0.24±0.49   0.42±0.70   0.55±0.91   0.68±1.12   0.76±1.22
   TT                   0.02±0.04   0.10±0.18   0.17±0.34   0.25±0.47   0.32±0.60   0.35±0.69
   *p*-value^a^         0.199       0.055       0.004^b^    0.007^b^    0.011^b^    0.017^b^
  *PRKAA2* rs10789038                                                               
   AA                   0.05±0.13   0.19±0.36   0.37±0.66   0.50±0.91   0.61±1.13   0.69±1.27
   AG                   0.09±0.28   0.31±0.56   0.52±0.73   0.67±0.85   0.79±0.95   0.87±0.99
   GG                   0.06±0.56   0.26±0.25   0.65±0.62   0.93±0.92   1.09±1.06   1.23±1.08
   *p*-value^a^         0.194       0.049^b^    0.080       0.085       0.089       0.020^b^

^a^ *p*-values calculated using analyses of covariance with gender, age, and baseline BMI (kg/m^2^) as covariates.

^b^ *p* \< 0.05.

^c^ The difference remained significant after the Bonferroni correction, which was set at *p* \< 0.0026 (0.05/19 SNPs).

*ANKK1,* ankyrin repeat kinase domain containing 1; *LEPR,* leptin receptor; *PRKAA2,* α2 catalytic subunit of AMPK; *SNP*, single nucleotide polymorphism ; VPA, valproic acid.

![The allelic association of (A) *LEPR* rs1137101 and (B) *ANKK1* rs1800497 with BMI change in patients with epilepsy (n = 212). Data are expressed as the mean ± standard error of the mean.](ijnppy_pyv021_f0001){#F1}

Association of VPA Css with Weight Change {#s9}
-----------------------------------------

After 6 months of treatment, 20.28% of patients were found to significantly gain weight (deﬁned as an increase of weight ≥7%), and the VPA Css of all patients were determined. However, the VPA Css in patents who gained significant weight were not different from those who did not gain weight (*p* = 0.121, Mann--Whitney U-test [Figure 2](#F2){ref-type="fig"}).

![Valproic acid (VPA) steady state plasma concentrations (Css) in epilepsy patients who gained (weight gained ≥7%) and did not gain weight (weight gained \<7%; n = 212).](ijnppy_pyv021_f0002){#F2}

Discussion {#s10}
==========

VPA-induced weight gain is the most frequent adverse effect of VPA treatment, resulting in various serious chronic diseases, but the underlying mechanism of the effect is still unknown. In the present study, we carried out a multi-gene analysis to study the role of genetic variants in VPA-induced weight gain, and we found, for the ﬁrst time, that polymorphisms of *LEPR*, *ANKK1,* and *PRKAA2* were associated with weight changes in Chinese Han epilepsy patients undergoing therapy with VPA. The genotypic association of *LEPR* rs1137101 and the allelic association of *LEPR* rs1137101 and *ANKK1* rs1800497 with weight gain remained significant after correcting for Bonferroni multiple testing (19 SNPs, *p* ~*corrected*~ = 0.0026). These results may deepen the understanding of the potential mechanisms in VPA-related weight gain and provide further evidence implicating genes involved in the regulation of food intake and energy homeostasis in this highly relevant adverse effect.

As LEP and LEPR play an important role in the regulation of body weight and maintenance of energy homeostasis, the inﬂuence of the variation *LEP* and *LEPR* genes on body weight, whether or not in combination with antipsychotic treatment, is currently being investigated ([@CIT0048]; [@CIT0020]). Of interest is the *LEPR* rs1137101 polymorphism (G allele mutated to A allele), leading to a single amino acid change---a glutamine (Q) for an arginine (R)---which could affect the functionality of the receptor and alter its signaling capacity ([@CIT0048]). Early reports have demonstrated that after treatment with VPA, patients who became obese showed increased serum LEP levels compared to patients who did not gain weight ([@CIT0045]). Our analyses indicate that carriers of the A-allele of *LEPR* rs1137101 have a higher risk of weight gain and BMI increase under VPA therapy. This result is in line with previous reports in which the A allele was associated with an increased risk of weight gain and metabolic syndrome in schizophrenia patients who received antipsychotics ([@CIT0020]; [@CIT0039]). Although the G allele appears to be protective against weight gain or metabolic syndrome, some studies found that the A allele was associated with a lower prevalence of obesity ([@CIT0048]; [@CIT0021]). Therefore, the function of the SNP should be investigated in the future research.

Dopamine receptors are involved in midbrain reward circuit activation ([@CIT0040]), and polymorphisms of *DRD2* have been found to be associated with altered perception of food reward and weight gain ([@CIT0008]; [@CIT0040]). Whether these variants are associated with drug-induced weight gain is unclear. The most commonly tested and referred to *DRD2* polymorphism is *ANKK1* rs1800497 (known as Taq IA), which has a single nucleotide change \[C(A2)/T(A1)\], that was shown to lie within the adjacent gene *ANKK1* ([@CIT0017]). Taq IA is located downstream of the termination codon of *DRD2,* has traditionally been considered to be a gene marker for *DRD2,* and is known to be a restriction fragment length polymorphism located in the coding region of *ANKK1*. It was reported that the Taq IA A1(T) allele was associated with a 7% weight gain in patients of European ancestry taking clozapine or olanzapine, but a negative association of Taq IA variation with weight change after treatment of dopamine agonists (Prolactinomas) was observed in a recent study ([@CIT0002]). However, the C-allele of *ANKK1* rs1800497 was found to be associated with a greater weight gain in our study. Thus, our observation is distinct from the previous reports. Possible explanations for the inconsistent ﬁndings with this SNP include heterogeneity with respect to the effects of these drugs to DRD2, sample size, population ethnicity, and study design. Future research should not only consider additional gene variants and functional analyses, but also analyze patients from multiple ethnic groups.

In the present study, the intronic SNP rs10789038 in the gene coding for *PRKAA2*, the α2 catalytic regulatory subunit of *AMPK,* was found to be associated with VPA-induced weight gain. Our result is similar to a previous report in which the G allele of rs10789038 was associated with an increased risk of weight gain after receiving antipsychotic drugs ([@CIT0036]). Although this result was not significant after taking into account multiple testing, further study is recommended to confirm this result. AMPK is expressed throughout the brain, and its activation in the hypothalamus is associated with increased food intake ([@CIT0032]). The literature has reported that VPA is an activator of AMPK ([@CIT0003]). Thus, studies in larger sample sets with SNPs covering the regulatory region of these genes coupled with functional analyses may shed light into their role in VPA-induced weight gain and other related metabolic disorders.

In the early literature, it was reported that the incidences of hair loss and weight gain increased with VPA Css at or above 100 μg/mL, and this is one of the reasons that the upper limit of the therapeutic range of VPA was defined at 100 μg/mL ([@CIT0025]; [@CIT0044]; [@CIT0009]). However, our study (*p* = 0.121, [Figure 2](#F2){ref-type="fig"}) and many others also demonstrated that there is no correlation between the degree of weight gain and the daily VPA dosage and serum VPA concentrations ([@CIT0037]; [@CIT0016]). Therefore, it is necessary to clarify the relationship between VPA Css and weight change with a large patient group.

Nevertheless, owing to the well-known confounding factors of pharmacogenetic studies, independent studies with larger patient groups and longer observation periods are needed to confirm these results.

In conclusion, we found evidence of an association between *LEPR* rs1137101and *ANKK1* rs1800497 with the occurrence of weight gain in Chinese epilepsy patients after treatment of VPA. The replication of these observations in independent samples is necessary before drawing any firm conclusions on the utility of these results for personalized medicine.
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